Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer: Hayward, California Tuesday, July 15, 2025, 13:00 Hrs [IST] Arcus Bioscience ...

PURPOSEGEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

One of the biggest obstacles in cancer treatment is drug resistance in cancer cells. Conventional efforts have focused on ...

A Taiwanese medical team has developed a new treatment for triple-negative breast cancer (TNBC) that tackles treatment-resistance, National Health Research Institutes (NHRI) president Sytwu Huey-kang ...

A team led by researchers from the Norwegian University of Science and Technology have found a new method to separate right- and left-handed molecules using circularly polarised light A new optical ...

Researchers have found a new way to optimise the design of molecular motors, bringing us one step closer to making synthetic molecular machines a reality ...

Single-molecule magnet could lead to stamp-sized hard drives capable of storing 100 times more data by Australian National University ...

The molecule that might save your sight—and your heart Fixing problems in cholesterol metabolism could stave off a leading cause of blindness, according to new research in mice, human plasma ...

A molecule made by the kidneys and found in certain foods can reproduce some of the myriad benefits of exercise — and slow some signs of ageing — when fed to mice 1.